{"schema_version":"1","generated_at":"2026-11-12T01:09:51.970Z","data_as_of":null,"url":"https://www.findmykol.com/kol/federico-sanchez","json_url":"https://www.findmykol.com/kol/federico-sanchez/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"federico-sanchez","name":"Federico Sanchez","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Waukesha","state":"WI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1396710836","openalex":"A5103819194"},"summary":"Federico Sanchez is an Oncology physician. OpenAlex indexes 32 publications with 234 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":32,"cited_by_count":234,"h_index":8,"latest_activity_year":2024,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"ShockWave Medical, Inc","program_year":2024,"amount_usd":102,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396710836"},{"payer":"Incyte","program_year":2021,"amount_usd":777.42,"payment_count":24,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396710836"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1396710836","source":"payments"},"prescribing":{"data_year":2021,"areas_total":8,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":24.7,"classes_total":2,"classes":[{"class":"Antimetabolite","setting":"prescribed","share_pct":16.3,"drugs":[{"name":"Hydroxyurea","share_pct":100}],"max_beneficiaries":null},{"class":"Purine Antimetabolite","setting":"prescribed","share_pct":8.4,"drugs":[{"name":"Azathioprine","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":22.9,"classes_total":3,"classes":[{"class":"Proton pump inhibitor","setting":"prescribed","share_pct":9.3,"drugs":[{"name":"Pantoprazole Sodium","share_pct":100}],"max_beneficiaries":null},{"class":"Corticosteroid","setting":"prescribed","share_pct":8.8,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]},{"area":"Blood & clotting","share_pct":17.2,"classes_total":2,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":11.5,"drugs":[{"name":"Xarelto","share_pct":100}],"max_beneficiaries":null},{"class":"Vitamin K antagonist","setting":"prescribed","share_pct":5.7,"drugs":[{"name":"Warfarin Sodium","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"mixed","data_year":2021,"office_pct":54.1,"facility_pct":45.9},"source":"medicare"},"publications":{"total":32,"shown":5,"withheld":27,"matched_by":"OpenAlex author record","recent":[{"title":"Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System","year":2024,"journal":"Journal of patient-centered research and reviews","source_url":"https://doi.org/10.17294/2330-0698.2060","status":"verified"},{"title":"Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital.","year":2023,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.e18716","status":"verified"},{"title":"Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital.","year":2022,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.e18799","status":"verified"},{"title":"MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).","year":2021,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2021.39.3_suppl.tps153","status":"verified"},{"title":"PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).","year":2021,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2021.39.3_suppl.tps143","status":"verified"}],"source":"works"},"contact":{"address_1":"N14W23833 STONE RIDGE DR","address_2":"SUITE 200","city":"Waukesha","state":"WI","zip":"531881157","phone":"262-513-2033","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1396710836","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":27}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-11-18","provider_certified":"2021-11-18","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2021}},"methodology_url":"https://www.findmykol.com/about#methodology"}